Press Releases

Bristol-Myers Squibb Company (NYSE:BMY) announced that 14 abstracts on Orencia have been accepted for presentation at the 2015 annual meeting of the European League Against Rheumatism (EULAR), to be held June 10-13 in Rome, Italy.  ...

Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that results from an interim analysis of its Phase III, randomized, open-label ELOQUENT-2 trial were published in the June 2 online edition of the New England Journal of Medicine. ...

Bristol-Myers Squibb Company (NYSE:BMY) will take part in Goldman Sachs 36th Annual Global Health Care Conference on Tuesday, June 9, 2015, in Rancho Palos Verdes, CA. Michael Giordano, senior vice president, Head of Development, Oncology, will answer questions about...

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab)+Yervoy (ipilimumab) regimen in patients with previously untreated advanced melanoma. ...

Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated patients with advanced squamous non-small cell lung cancer.   At one...

Bristol-Myers Squibb Company (NYSE:BMY) today announced positive results of a Phase III trial (CheckMate -067) evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen or Opdivo monotherapy vs.   Yervoy monotherapy in patients with previously untreated advanced melanoma. Both...

Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015. Jeffrey Simmons, senior vice president and president, Elanco Animal Health, will participate in a fireside chat at 2:20...